パーキンソン病（PD）：7市場の医薬品の予測と市場の分析

2023年のPD治療薬の売上は、主要7市場全体で推定約34億米ドルでした。

米国が2023年に推定21億米の医薬品売上でPD市場を独占し、主要7市場の売上の63.3%を占めました。この高い市場シェアは主に、PD有病者人口が多いことに加え、米国では主要7市場の他国に比べて医薬品のコストが非常に高いことに起因します。欧州5ヶ国市場の2023年の売上は6億7,430万米ドルで、世界市場の20.0%を占めました。日本の2023年の売上は5億6,040万米ドルで、世界市場全体の16.6%を占めました。

PD市場は2033年までに約79億米ドルに達すると予測され、CAGRで8.9%の成長が見込まれます。米国は2033年もマーケットリーダーの地位を維持すると予測されます。

当レポートでは、パーキンソン病（PD）の主要7市場（米国、欧州5ヶ国、日本）について調査し、疾患の概要、市場の収益と予測、パイプラインの分析、現在と将来の競合の分析などを提供しています。

目次

第1章 パーキンソン病：エグゼクティブサマリー

• PD市場は79億米ドルに達する
• 新たな対症療法がPD市場を形成し続ける
• PD市場への疾患修飾療法の参入の機会と課題
• 医師の考え

第2章 イントロダクション

第3章 疾患の概要

• 病因と病態生理学
  • 病因
  • 病態生理学
• 病気分類システム

第4章 疫学

• 疾患の背景
• 危険因子と合併症
• 世界の過去の動向
• 予測手法
• PDの疫学的予測（2023年～33年）
  • PDの患者数
  • PDの患者数：年齢別
  • PDの患者数：性別
  • PDの患者数：HY臨床病期分類別
  • PDの患者数：タイプ別
  • PDの患者数：遺伝型別
  • PDの患者数：運動合併症別
  • PDの患者数：神経精神医学的合併症別
• 議論
  • 疫学的予測の考察
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第5章 疾病管理

• 診断と治療の概要
• 疾病管理に関するKOLの考察

第6章 現在の治療オプション

• 概要

第7章 アンメットニーズと機会の評価

• 概要
• 運動合併症の効果的な治療 - ジスキネジア、オフエピソード、歩行、バランス障害
• 非運動合併症に対する新たな治療法 - 精神病と認知症
• 神経保護剤または疾患修飾剤
• 錠剤の負担を軽減する処方

第8章 研究開発戦略

• 概要
  • 新たな標的の開発 - 細胞・遺伝子治療とαシヌクレインを標的として
  • 革新的なドラッグデリバリーシステム
  • 二次適応症、上市後要件、医薬品の再利用
• 臨床試験の設計
  • 疾患進行の信頼できるバイオマーカー
  • パーキンソン病の遺伝的サブタイプを知るには遺伝学的研究が必要である

第9章 パイプライン評価

• 概要
• 臨床開発中の有望な医薬品

第10章 パイプライン評価の分析

• 概要
• 競合の評価
  • レボドパ療法
  • ドーパミン作動薬/併用
  • 運動合併症を標的とした抗パーキンソン病薬
  • PD認知症をターゲットにしたアセット
  • 神経保護剤と疾患修飾剤

第11章 現在の企業と将来の企業

• 概要
• 取引動向

第12章 市場見通し

• 世界市場
  • 予測
  • 促進要因と障壁 - 世界の問題
• 米国
  • 予測
  • 主なイベント
  • 促進要因と障壁
• 欧州5ヶ国
  • 予測
  • 主なイベント
  • 促進要因と障壁
• 日本
  • 予測
  • 主なイベント
  • 促進要因と障壁

第13章 付録

This report covers the 7 major markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033.

GlobalData estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM.

With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM. The 5EU market contributed $674.3 million in sales in 2023, accounting for 20.0% of the global market. Japan contributed sales of $560.4 million in 2023, representing 16.6% of the total global market.

GlobalData anticipates that the PD market will grow to be worth approximately $7.9 billion by 2033, at a compound annual growth rate (CAGR) of 8.9%. The US is expected to maintain its position as the market leader in 2033

Scope

• Overview of Parkinson's Disease, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized Parkinson's Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Parkinson's therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Parkinson's treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global Parkinson's Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM Parkinson's Disease therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Parkinson's Disease therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Parkinson's Disease: Executive Summary

• 1.1 The PD market will grow to $7.9 billion
• 1.2 Novel symptomatic treatments will continue to shape the PD market
• 1.3 Opportunities and challenges for disease-modifying therapies entering the PD market
• 1.4 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming related reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
• 3.2 Classification or staging systems

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 Forecast methodology
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods
  • 4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of PD
  • 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of PD by HY clinical staging
  • 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PD by inheritance type
  • 4.4.6 Forecast assumptions and methods: diagnosed prevalent cases of PD by motor complications
  • 4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of PD by neuropsychiatric complications
• 4.5 Epidemiological forecast for PD (2023-33)
  • 4.5.1 Diagnosed prevalent cases of PD
  • 4.5.2 Age-specific diagnosed prevalent cases of PD
  • 4.5.3 Sex-specific diagnosed prevalent cases of PD
  • 4.5.4 Diagnosed prevalent cases of PD by HY clinical staging
  • 4.5.5 Diagnosed prevalent cases of PD by type
  • 4.5.6 Diagnosed prevalent cases of PD by inheritance type
  • 4.5.7 Diagnosed prevalent cases of PD by motor complications
  • 4.5.8 Diagnosed prevalent cases of PD by neuropsychiatric complications
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 KOL insights on disease management

6 Current Treatment Options

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Effective treatment of motor complications - dyskinesia, off episodes, gait, and balance problems
• 7.3 New therapies for non-motor complications - psychosis and dementia
• 7.4 Neuroprotective or disease-modifying agents
• 7.5 Formulations that reduce pill burden

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 Development of novel targets - targeting cell and gene therapies and a-synuclein
  • 8.1.2 Innovative drug delivery systems
  • 8.1.3 Secondary indications, post marketing requirements, and drug repurposing
• 8.2 Clinical trials design
  • 8.2.1 Reliable biomarkers of disease progression
  • 8.2.2 Genetic studies required to learn about genetic subtypes of PD

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment
  • 10.2.1 Levodopa therapies
  • 10.2.2 Dopamine agonists/combinations
  • 10.2.3 Antiparkinsonian agents targeting motor complications
  • 10.2.4 Assets targeting PD dementia
  • 10.2.5 Neuroprotective and disease-modifying agents

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - KOLs interviewed for this report
• 13.5 Primary research - prescriber survey
• 13.6 About the Authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Epidemiologist
  • 13.6.4 Managing Epidemiologists
  • 13.6.5 Vice President of Disease Intelligence and Epidemiology
  • 13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Contact Us